Kiora Pharmaceuticals, Inc.
KPRX
$3.32
$0.03090.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.00M | 16.00M | 16.00M | 16.00M | -- |
| Total Other Revenue | 20.00K | 20.00K | 20.00K | -- | -- |
| Total Revenue | 16.02M | 16.02M | 16.02M | 16.00M | -- |
| Cost of Revenue | 379.50K | 1.21M | 979.50K | 1.46M | 409.50K |
| Gross Profit | 15.64M | 14.81M | 15.04M | 14.54M | -409.50K |
| SG&A Expenses | 5.54M | 5.10M | 5.13M | 4.69M | 4.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.44M | 9.93M | 9.73M | 9.77M | 8.69M |
| Operating Income | 5.58M | 6.09M | 6.29M | 6.23M | -8.69M |
| Income Before Tax | 5.66M | 5.64M | 3.29M | 2.90M | -12.42M |
| Income Tax Expenses | 2.07M | 90.30K | 90.30K | 90.30K | 90.30K |
| Earnings from Continuing Operations | 3.59 | 5.55 | 3.20 | 2.81 | -12.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.59M | 5.55M | 3.20M | 2.81M | -12.51M |
| EBIT | 5.58M | 6.09M | 6.29M | 6.23M | -8.69M |
| EBITDA | 5.60M | 6.12M | 6.32M | 6.27M | -8.64M |
| EPS Basic | 2.32 | 0.61 | -6.55 | -13.17 | -26.86 |
| Normalized Basic EPS | 1.93 | 0.72 | -0.77 | -4.68 | -12.60 |
| EPS Diluted | 1.08 | -0.64 | -7.80 | -14.42 | -26.86 |
| Normalized Diluted EPS | 1.18 | -0.04 | -1.53 | -5.43 | -12.60 |
| Average Basic Shares Outstanding | 15.49M | 12.10M | 8.68M | 4.87M | 2.20M |
| Average Diluted Shares Outstanding | 16.50M | 13.11M | 9.69M | 5.88M | 2.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |